NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Mozart Therapeutics

Mozart Therapeutics

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://www.mozart-tx.com/

Last Round

Series A

Extension

Jun 7, 2023

Total Funding Raised

$80M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Mozart Therapeutics is a biotechnology company that develops disease-modifying therapies for autoimmune and inflammatory diseases by targeting the CD8 T regulatory cell network.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyautoimmune diseaseregulatory T cellTregimmunologydrug discoveryclinical-stage biotechtype 1 diabetesimmune homeostasisbiologicsprecision medicinetherapeutic candidateclinical trialsimmune modulationnext-gen immunology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Mozart Therapeutics Comparables

Compare Mozart Therapeutics with similar companies based on industry and business-model similarity.

Mozart Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
GentiBio
87%
Quell Therapeutics
86%
Avotres Inc.
84%

Mozart Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionJun 7, 2023
Series AOct 26, 2021

Key People

Founding team and executive leadership

Russ Hawkinson

Chief Financial Officer

Executive Team

Mozart Therapeutics Investors

Notable investors and investment history

Mozart Therapeutics investors
InvestorRounds
Altitude Life Science VenturesSeries A, Series A Extension
ARCH Venture PartnersSeries A Extension, Series A
ARCH Venture PartnersSeries A Extension, Series A, Seed
AbbVie VenturesSeries A Extension
Alexandria Venture InvestmentsSeries A, Series A Extension
Pfizer VenturesSeries A Extension
Sofinnova PartnersSeries A Extension, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 23, 2026

    Presented interim Phase Ib results at the Immunology of Diabetes Society Congress.

  • Apr 23, 2026

    Positive interim Phase Ib results for MTX-101 in type 1 diabetes patients.

Mozart Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Mozart Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Mozart Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range36
Year Founded2020
Last FundingJun 7, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.